低分子肝素钙治疗急性脑梗死病人的临床观察

目的观察低分子肝素钙治疗急性脑梗死的临床疗效及对实验室指标的影响。方法将81例急性脑梗死病人随机分成低分子肝素钙治疗组(41例)和常规治疗对照组(40例)。治疗前及治疗后10d、30d进行疗效评定,并监测实验室指标,进行统计学分析。结果治疗组的神经功能缺损评分减少的百分率明显大于对照组(P<0.05),血液流变学指标治疗组均有明显改变,血小板计数和出凝血时间无明显变化。结论低分子肝素钙治疗急性脑梗死疗效肯定,不良反应少。

The clinical observation of low-molecular-weight heparin calcium in treating the patients with acute cerebral infarction

Objective: To investigate the clinical effectiveness of low molecular weight heparin calcium (LMWHC) in treating the patients with acute cerebral infarction and the influence of it on laboratory indexes. Methods: Eighty one patients with acute cerebral infarction were randomly assigned to LMWHC treatment group (41 patients) and routine treatment control group (40 patients). The clinical effectiveness was observed after treatment for 10 days and 30 days, respectively, and laboratory indexes were monitored and analyzed statistically. Results: The improvement of scores of nervous system damage and the changes of hemorheological indexes of the treatment group were better than those of the control group, but the platelet count, the bleeding time and coagulation time had no evident changes. Conclusion: The effectiveness of LMWHC in treating patients with acute cerebral infarction is definite and little adverse reactions occurred.